Our study suggests that targeting S1P/S1PR2/STAT3/miR-135b/β-TrCP/YAP/Notch3 might have potential value in ameliorating PASMCs hyperproliferation and benefit PAH. Here, S1PR2 is linked to pulmonary arterial hypertension.